Skip to content

Geron GERN Other Commercial Liabilities

Other Commercial Liabilities at other companies

Incyte logo
IncyteINCY
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
GRAIL, Inc. logo
GRAIL, Inc.GRAL
Omeros logo
OmerosOMER

Other financials

Income statement

See full
Revenue$51.8M+30.9%
Operating income$158.0K+101%
Net income-$3.6M+81.6%
EPS (diluted)-$0.01+66.7%

Balance sheet

See full
Cash & equivalents$48.7M-12.2%
Total debt$134.0M+10.0%
Total equity$229.1M-14.6%
Total assets$534.1M-5.0%

Cash flow

See full
Operating cash flow-$62.9M-31.1%
CapEx$206.0K+2.0%
Free cash flow-$43.8M-6.8%

Valuation

See full
Market cap$878.88M-8.6%
Enterprise value$964.15M-6.2%
P/S4.7×-172×

Profitability

See full
Operating margin-705.5%-351pp
Net margin-682.5%-339pp
FCF margin-734.4%-365pp

Returns & leverage

See full
Return on equity-27.1%-7.8pp
Debt / equity0.6×+0.1×
Current ratio6.8×-1.1×

Where this comes from

Reported directly by Geron in its filing.

Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.

The official record: Geron’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Geron's other commercial liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Geron's other commercial liabilities?
Geron (GERN) reported other commercial liabilities of $30.97M in Q1 2026.
How has Geron's other commercial liabilities changed year-over-year?
Geron's other commercial liabilities increased by 7.2% year-over-year, from $28.89M to $30.97M.
What is the long-term trend for Geron's other commercial liabilities?
Over 5 years (2020 to 2025), Geron's other commercial liabilities has grown at a 28.0% compound annual growth rate (CAGR), from $14.93M to $51.34M.